Elanco to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

Elanco (NYSE: ELAN) will participate in the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026. Jeff Simmons, president and CEO, and Bob VanHimbergen, executive vice president and CFO, will represent the company and respond to questions from analysts at 3:45 p.m. PST (6:45 p.m. EST).

A live audio webcast will be available in the Events and Presentations section of Elanco's investor website, and a replay will be available for a limited time after the event.

News Market Reaction – ELAN

+3.25%

1 alert

+3.25% News Effect

On the day this news was published, ELAN gained 3.25%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Conference date: January 13, 2026 Presentation time PST: 3:45 p.m. PST Target free cash flow: $1B +5 more

8 metrics

Conference date January 13, 2026 J.P. Morgan Healthcare Conference appearance

Presentation time PST 3:45 p.m. PST Analyst Q&A session timing

Target free cash flow $1B Expected from 2026–2028 per Investor Day

Innovation revenue $1.1B Forecast innovation revenue in 2026

Canine dermatology market $1.3B Estimated U.S. canine dermatology market for Befrena

Befrena dosing interval 6–8 weeks Recommended dosing interval for Befrena

Current share price $23.05 Pre‑news price on analysis date

52-week range $8.02 – $23.7 52-week low and high before this news

Market Reality Check

Price: $23.36 Vol: Volume 4,934,199 is below...

normal vol

$23.36 Last Close

Volume Volume 4,934,199 is below the 20-day average of 5,710,008 (relative volume 0.86). normal

Technical Price at 23.05, trading above the 200-day moving average of 16.6 and within 2.74% of the 52-week high 23.7.

Peers on Argus

Peers show mixed moves with both gains and losses: for example, INDV up 2.52%, L...

Peers show mixed moves with both gains and losses: for example, INDV up 2.52%, LNTH up 2.85%, PBH up 2.59%, while ALKS and VTRS are slightly down.

Historical Context

5 past events · Latest: Dec 31 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Dec 31	USDA product approval	Positive	-0.6%	USDA approval of Befrena for canine allergic and atopic dermatitis.
Dec 18	FDA conditional ok	Positive	+0.1%	FDA conditional approval for Credelio Quattro-CA1 to treat screwworm in dogs.
Dec 09	Investor Day targets	Positive	-5.8%	Three‑year plan with growth, leverage and free cash flow targets to 2028.
Nov 26	Board observer role	Positive	-0.2%	Elanco executive appointed board observer at Neurizon under license deal.
Nov 21	FDA EUA granted	Positive	+4.8%	FDA Emergency Use Authorization for Credelio CAT to treat screwworm in cats.

Pattern Detected

Recent positive operational and regulatory news often saw mixed or negative next-day price reactions, with only some approvals aligning with positive moves.

Recent Company History

This announcement follows a series of regulatory wins and strategic updates. In late 2025, Elanco gained USDA approval for Befrena, targeting the $1.3 billion U.S. canine dermatology market with a planned H1 2026 launch, and secured FDA conditional approval and an EUA for Credelio products addressing screwworm in dogs and cats. An Investor Day on Dec 9, 2025 set targets for mid‑single digit organic revenue growth and at least $1B free cash flow from 2026–2028. The current conference appearance fits into this ongoing investor communication effort.

Market Pulse Summary

This announcement highlights Elanco’s planned participation at a major healthcare conference on Janu...

Analysis

This announcement highlights Elanco’s planned participation at a major healthcare conference on January 13, 2026, where senior leadership will engage with analysts via a webcast. It follows late‑2025 updates including new product approvals and long‑term targets such as at least $1B in free cash flow from 2026–2028. Investors may watch for any updated guidance, pipeline commentary, or strategic shifts discussed at the event and how these compare with prior Investor Day objectives.

Jargon Translator

conditional approval

Conditional approval is a formal confirmation that a product or plan is permitted to proceed, provided certain specified requirements are met within a designated timeframe. For investors, it signals that approval is nearly complete but depends on the fulfillment of specific conditions, which could influence the final outcome or timeline. This status helps stakeholders assess the likelihood of success while identifying any remaining hurdles.

deferred stock units

Deferred stock units are promises from a company to give an employee shares of stock at a future date, often after certain conditions are met or after leaving the company. They function like a form of delayed compensation, allowing employees to earn shares over time. For investors, they represent potential future ownership in the company, but do not provide immediate voting rights or dividends until the shares are actually received.

emergency use authorization

A regulatory emergency use authorization allows a government health agency to temporarily permit the use or sale of a medical product—such as a vaccine, test, or treatment—before full formal approval when there is a public health crisis. For investors, an authorization can rapidly open revenue and market access while carrying higher regulatory and demand risk, like a fast-track pass that speeds a product to customers but may still require further review and can affect a company's valuation and future sales prospects.

AI-generated analysis. Not financial advice.

INDIANAPOLIS, Jan. 6, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) will participate in the 44^th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026. Jeff Simmons, president and CEO, and Bob VanHimbergen, executive vice president and CFO, will represent the company and respond to questions from analysts at 3:45 p.m. PST (6:45 PM EST).

A live audio webcast will be available in the "Events and Presentations" section of Elanco's investor website. A replay will be available for a limited time at the conclusion of the event.

ABOUT ELANCO
Elanco Animal Health Incorporated (NYSE: ELAN) is a global leader in animal health dedicated to innovating and delivering products and services to prevent and treat disease in farm animals and pets, creating value for farmers, pet owners, veterinarians, stakeholders and society as a whole. With 70 years of animal health heritage, we are committed to breaking boundaries and going beyond to help our customers improve the health of animals in their care, while also making a meaningful impact on our local and global communities. At Elanco, we are driven by our vision of Food and Companionship Enriching Life and our purpose – all to Go Beyond for Animals, Customers, Society and Our People. Learn more at www.elanco.com.

Investor Contact: Tiffany Kanaga (765) 740-0314 tiffany.kanaga@elancoah.com
Media Contact: Colleen Parr Dekker (317) 989-7011 colleen.dekker@elancoah.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/elanco-to-participate-in-the-44th-annual-jp-morgan-healthcare-conference-302653013.html

SOURCE Elanco Animal Health

FAQ

When will Elanco (ELAN) present at the J.P. Morgan Healthcare Conference in 2026?

Elanco will present on Tuesday, January 13, 2026 at 3:45 p.m. PST (6:45 p.m. EST).

Who will represent Elanco (ELAN) at the January 13, 2026 presentation?

Jeff Simmons, president and CEO, and Bob VanHimbergen, executive vice president and CFO, will represent Elanco and answer analyst questions.

How can investors listen to Elanco's (ELAN) J.P. Morgan presentation?

A live audio webcast will be available in the Events and Presentations section of Elanco's investor website.

Will there be a replay of Elanco's (ELAN) J.P. Morgan presentation?

Yes. A replay will be available for a limited time at the conclusion of the event on the company's investor website.

Will Elanco (ELAN) provide earnings or guidance during the January 13, 2026 session?

The announcement only notes that executives will respond to analyst questions; it does not disclose earnings or guidance.

Where on Elanco's site will the J.P. Morgan webcast be posted for ELAN investors?

The live audio webcast and limited-time replay will be posted in the Events and Presentations section of Elanco's investor website.